耀才团队: 港股短期势头仍属乐观
耀才研究部称,美国疫情至今仍未见有任何改善,美国新冠病毒确诊个案激增,但特朗普在独立日言论利好市况,表示不用年底就可研制出疫苗。而市场目前正关注特朗普会否在短期内公布两至三项应对中国的行动。道指期货及「黑期」今早(6日)升逾百点,港股於短期後市有条例续向上试高位,恒指短线有望企稳25,000点关口之上,只要中美关系未有显着转差,整个上升势头该有望延续。个股方面,近来热炒的中芯国际(00981.HK)将於科创板上市,公布A股发行价为每股27.46元人民币,虽然较港股上周五收市价折让逾9%,但由於市场普遍预期中芯A股上市後将会大幅抽升,料H股短期後市表现将会仍较为波动。
技术上看,港股於上周五成功突破6月24日之高位25,303点,整个形态正有利恒指进一步上试250天线,即指数有望一试26,000点关口,以修补3月9日之下跌裂口。
(笔者为证监会持牌人)~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.